Top Markets
#1 Akedo Akedo +84.18%
#2 TENDIES TENDIES +73.28%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.58%
#5 Mubarak Mubarak +31.80%
#6 MultiversX MultiversX +27.43%
#7 Bitway Bitway +26.80%
#8 Cash Cat Cash Cat +24.01%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Mabpharm Limited Mabpharm Limited

Mabpharm Limited

2181
Peringkat dalam Saham #17595
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research,... Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Harga Saham
$0.05692717
Kapitalisasi Pasar
$234.77M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-44.45%
Negara
CN
Perdagangan Mabpharm Limited (2181)

Kategori

Healthcare
Rasio P/E untuk Mabpharm Limited (2181)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Mabpharm Limited, rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Mabpharm Limited dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.